

Therapeutic Potential of Tumor Treating Fields for Malignant Brain Tumors

Yoyou Zhou¹, Xiaoqing Xing¹, Jinyun Zhou¹, Han Jiang², Peili Cen¹, Chentao Jin¹, Yan Zhong¹, Rui Zhou¹, Jing Wang¹, Mei Tian¹, and Hong Zhang¹

¹Zhejiang University

²University of Macau

January 20, 2023

Abstract

Background Malignant brain tumors are among the most threatening diseases of the central nervous system, and despite increasingly updated treatments, the prognosis has not been improved. Tumor treating fields (TTFields) are an emerging approach in cancer treatment using intermediate-frequency and low-intensity electric field, and can lead to development of novel therapeutic options. Recent findings A series of biological processes induced by TTFields to exert anti-cancer effects have been identified, and applications of TTFields in oncology have been increasingly reported. This review addresses the mechanisms of TTFields and recent advances in the application of TTFields therapy in malignant brain tumors, especially in glioblastoma (GBM). **Conclusions** As a novel therapeutic strategies, TTFields have shown promising results in many clinical trials, especially in GBM, and continue to evolve. A growing number of patients with malignant brain tumors are being enrolled in ongoing clinical studies demonstrating that TTFields-based combination therapies can improve treatment outcomes.

Therapeutic Potential of Tumor Treating Fields for Malignant Brain Tumors

Yoyou Zhou^{1,2,3}, Xiaoqing Xing^{1,2,3}, Jinyun Zhou^{1,2,3}, Han Jiang⁴, Peili Cen^{1,2,3}, Chentao Jin^{1,2,3}, Yan Zhong^{1,2,3}, Rui Zhou^{1,2,3}, Jing Wang^{1,2,3*}, Mei Tian^{1,2,3,7*}, Hong Zhang^{1,2,3,5,6*}

¹Department of Nuclear Medicine and PET Center, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. ²Institute of Nuclear Medicine and Molecular Imaging, Zhejiang University, Hangzhou, Zhejiang, China. ³Key Laboratory of Medical Molecular Imaging of Zhejiang Province, Hangzhou, Zhejiang, China. ⁴Biomedical Imaging Laboratory (BIG), Department of Electrical and Computer Engineering, Faculty of Science and Technology, University of Macau, Taipa, Macau SAR, China. ⁵College of Biomedical Engineering and Instrument Science, Zhejiang University, Hangzhou, Zhejiang, China. ⁶Key Laboratory for Biomedical Engineering of Ministry of Education, Zhejiang University, Hangzhou, Zhejiang, China. ⁷Human Phenome Institute, Fudan University, Shanghai, China.

* Corresponding Authors:

Prof. Hong Zhang, Department of Nuclear Medicine, The Second Affiliated Hospital of Zhejiang University, 88 Jiefang Road, Hangzhou, Zhejiang, China. E-mail: hzhang21@zju.edu.cn

Prof. Mei Tian, Department of Nuclear Medicine, The Second Affiliated Hospital of Zhejiang University, 88 Jiefang Road, Hangzhou, Zhejiang, China. E-mail: tianmei@fudan.edu.cn

Jing Wang, Department of Nuclear Medicine, The Second Affiliated Hospital of Zhejiang University, 88 Jiefang Road, Hangzhou, Zhejiang, China. E-mail: wangjing5678@zju.edu.cn

Yoyou Zhou and Xiaoqing Xing are the co-first author.

Abstract

Background

Malignant brain tumors are among the most threatening diseases of the central nervous system, and despite increasingly updated treatments, the prognosis has not been improved. Tumor treating fields (TTFields) are an emerging approach in cancer treatment using intermediate-frequency and low-intensity electric field, and can lead to development of novel therapeutic options.

Recent findings

A series of biological processes induced by TTFields to exert anti-cancer effects have been identified, and applications of TTFields in oncology have been increasingly reported. This review addresses the mechanisms of TTFields and recent advances in the application of TTFields therapy in malignant brain tumors, especially in glioblastoma (GBM).

Conclusions

As a novel therapeutic strategies, TTFields have shown promising results in many clinical trials, especially in GBM, and continue to evolve. A growing number of patients with malignant brain tumors are being enrolled in ongoing clinical studies demonstrating that TTFields-based combination therapies can improve treatment outcomes.

Key words: Tumor Treating Fields (TTFields); Alternating electric field; Cancer therapy; Malignant brain tumors; Glioblastoma (GBM).

Abbreviations

AMPK: AMP-dependent kinase; BBB: Blood-brain-barrier; BPC: Best physician's choice chemotherapy; CCF: Cytokinetic cleavage furrow; DSBs: DNA double-strand breaks; DSC-PWI: Dynamic susceptibility contrast-perfusion weighted imaging; DTI: Diffusion tensor imaging; ECM: Extracellular matrix; EF: Electric field; EMT: Epithelial-mesenchymal transition; FDA: The US Food and Drug Administration; ^{18}F -FDG: ^{18}F -2-fluoro-2-deoxy-D-glucose; FET: O-(2- ^{18}F -fluoroethyl)-L-tyrosine; AMT: Alpha[^{11}C]-methyl-L-tryptophan; ^{18}F -DASA-23: 1-((2-fluoro-6- ^{18}F -fluorophenyl)sulfonyl)-4-((4-methoxyphenyl)sulfonyl)piperazine; PKM2: Pyruvate kinase M2; GBM: Glioblastoma; HIF1 α : Hypoxia-inducible factor 1 α ; HMGB1: High-mobility group box 1; MA: Mesenchymal astrocytoma; MMP: matrix metalloproteinase; MPS1: Monopolar spindle 1; MRI: Magnetic resonance imaging; ndGBM: Newly diagnosed glioblastoma; NF- κ B: Nuclear factor kappa-B; NSCLC: Non-small cells lung cancer; OS: Overall survival; PD-1: Programmed cell death protein 1; PET: Positron emission tomography; PFS: Progression-free survival; PKM2: Pyruvate kinase M2; rGBM: Recurrent glioblastoma; RT: Radiation treatment; SOC: Standard of care; SRS: Stereotactic radiosurgery; TMZ: Temozolomide; T1IFNs: Type 1 interferons; TTFields: Tumor treating fields; VEGF: Vascular endothelial growth factor.

INTRODUCTION

Malignant brain tumors are the most devastating disease in the central nervous system which seriously threatening human health. Among them, glioblastoma multiforme (GBM) is the most common and deadliest primary neoplasm with high mortality and inevitable recurrence[1]. Despite the extensive development of multidisciplinary treatment approaches involving extensive surgery, chemotherapy and radiotherapy, the prognosis of GBM remains discouraging. Conventional approaches provide limited effectiveness for malignant brain tumors due to late diagnosis, unspecific location, and tumor heterogeneity, leading to unbearable adverse effects[2, 3]. Targeted therapy and immunotherapy (e.g., gefitinib and trastuzumab) have shown modest efficacy, because of the poor permeability of blood-brain-barrier (BBB)[4-6]. Therefore, it's urgent to develop a more effective and safer therapy.

TTFields are a novel tumor therapy which inhibit the proliferation and growth of tumor by delivering alternating electrical field (EF) at low intensity (1-3 V/cm) and intermediate frequency (100-300 kHz)[7].

As a physical local therapy, TTFields do not cause serious systemic side effects and without therapeutic resistance[8, 9]. With the excellent clinical outcomes had been reported, TTFields have already been approved by the US Food and Drug Administration (FDA) for the treatment of patients with newly diagnosed glioblastoma (ndGBM), recurrent glioblastoma (rGBM), and malignant pleural mesothelioma[8-10].

Afterwards, breakthroughs have been made in the in vitro or animal studies on the biological mechanisms of TTFields. Along with the preclinical research, clinicians have carried out some significant trials of TTFields, including the combined treatments or triple treatment, making TTFields a promising candidate in combination with other therapies. In this article, we will review the anti-tumor mechanism of TTFields and discuss the emerging framework of TTFields-based combination therapy for malignant brain tumors.

ANTI-TUMOR MECHANISMS OF TTFIELDS

Tissues and cells possess endogenous EF that influence biological activities and cellular events. The biological circuitry of cancer cells is modified, and manipulating their bioelectrical properties may lead to new modalities for cancer treatment[11]. Exogenous EF has been long exploited for interference and/or stimulation of certain natural biological processes, such as depolarization of nerves, contraction of muscles, embryonic development and heat production of tissues[12]. Intermediate-frequency alternating EF had been neglected by the capacity of neither generating heat nor triggering action potentials[13]. Emerging studies have reported that TTFields can alter the bioelectrical state of macromolecules and organelles involved in cancer biology, thus showcasing the therapeutic potential to against tumors in multiple ways. Moreover, the whole proteomic and transcriptomic analyses proved the massive alteration of differentially expressed proteins, mRNAs, miRNAs, lncRNAs, and circRNAs by TTFields in GBM cells which are related to cell mitosis-related events, varied cellular biological processes, and multiple organelle structures and activities[14].

TTFields interfere with cancer cell mitosis

The inhibition of cell mitosis is the most common reported mechanism of TTFields, and TTFields targets cancer cells through the unusual electrical polarity and rapid proliferative properties. Considering that all charged particles and dipoles in cell will respond to EF/currents and will oscillate as EF forces alternate in opposite directions[15], and dividing cells contain highly polar, spatially oriented microtubules and septins, TTFields are capable of interfering with cell mitosis and leading to arrest of proliferation[7]. Specifically, during normal metaphase, tubulins are precisely choreographed and arranged to form microtubule spindles that extend into the genetic material lining the center of the cell and bind to chromosomes[16, 17]. When exposed to TTFields, tubulin is forced to align along the direction of EF, resulting in the interference of tubulin polymerization and obstruction of microtubule spindle formation (Figure 1A)[7]. Another important basis of the effect of TTFields in dividing cells is the directional, hourglass-shaped cell morphology during the cytokinesis phase[7]. At the late stage of cell mitosis, the mitotic septin complex composes of septin 2, 6, and 7, which will be repositioned in alternating EF, leading to aberrant localization of the cytokinetic cleavage furrow (CCF), which results in improper cell division[18]. Septins cross-link to F-actin bundles within the submembrane actin cytoskeleton and must be sufficiently stiff to withstand the hydrostatic pressure generated within the cytoplasm by the invasion of CCF[19, 20]. {Gilden, 2012 #415; Tooley, 2009 #416; Tooley, 2009 #416} In cytokinesis, the applied EF intensity in dividing cell shows an hourglass-like non-uniform field distribution, and all polar macromolecules and organelles will be pushed towards the CCF where the EF intensity is highest (Figure 1B)[21-23]. This so-called mesoelectrophoresis prevents cells from dividing properly. Catastrophic mitotic errors occur in late mitosis are impossibly rectified, and the cell membrane will rupture and blister[24].

TTFields disrupt genomic integrity

During interphase, TTFields possess the function of disrupting the integrity of genome, leading to efficient cytotoxic actions against tumor cells. The phosphorylation level of γ -H2AX, an indicator of DNA damage, was higher when combining TTFields with radiation treatment (RT) than RT alone[25]. RT-induced cytotoxicity depends on the extent of DNA double-strand breaks (DSBs) repair, most of which are repaired within 24 hours after RT. In TTFields-treated cells after RT, more than 40% of DSB failed to be repaired, indicating

the efficacy of TTFields to enhance RT-damaged DNA may through blocking the homologous recombination repair pathway[26]. The expression of BRCA1 pathway genes was found significantly down-regulated during TTFields treatment[27]. BRCA1 pathway not only plays a vital role in homologous recombinant DNA repair[28], but maintains the stability of DNA replication forks in association with the Fanconi anemia proteins and promotes alternative end-joining DNA repair[29]. Therefore, DNA replication stress increased by TTFields, including the reduction of replication fork speed and the increase in R-loop formation, resulting in the disruption of DNA integrity[30]. In turn, TTFields not only slow DNA damage repair kinetics but induce replication stress in cancer cells, and the end is cell death (Figure 1C).

TTFields inhibit cell migration and invasion

TTFields have been reported with the capacity to inhibit the metastatic spread of solid tumors[31]. Tumor metastasis is a multi-step process, including tumor cell invasion of basement membranes and movement to surrounding tissues, intravasation into blood vessels, and spreading to other organ sites. It's well known that microtubules in TTFields-treated cells tend to align with the EF. Alterations of microtubules lead to the mediation of the GEF-H1/RhoA/ROCK signaling pathway and the consequent formation of focal adhesions and induction of peripheral actin bundling, thereby hindering the motility of cancer cells (Figure 1D)[18]. TTField also exert the suppression of ciliogenesis in GBM cell lines which related with the development of tumor and the resistance to therapy[32].

Epithelial-mesenchymal transition (EMT) programs contribute to the acquisition of aggressive properties by enhancing the motility of cancer cells, damaging the intercellular junctions, and remodeling the extracellular matrix (ECM)[33]. EMT-related biomarkers in GBM cells were found significantly affected by TTFields involving a series of potential mechanisms. Remarkably, mesenchymal markers (e.g., vimentin, smooth muscle actin) were down-regulated, while epithelial markers (e.g., the adherens junction protein E-cadherin) was up-regulated, and its loss serves as the core role in the loss of epithelial differentiation[34]. ECM is the first tissue barrier to prevent tumor invasion peripherally which can be degraded by matrix metalloproteinases (MMPs). TTFields can inhibit the degradation of ECM by suppressing the expression of nuclear factor kappa-B (NF- κ B), a transcription factor that regulates the expression of MMPs[34, 35]. Besides, the migration and invasion of cancers require an adequate supply of oxygen and nutrients, hence neovascularization is a decisive factor in cancer progression[36]. The levels of hypoxia-inducible factor 1 α (HIF1 α) and vascular endothelial growth factor (VEGF) were decreased in TTFields-treated cells, leading to reduced angiogenesis[34]. Furthermore, a significant time-dependent inhibition in PI3K/AKT and MAPK signaling was observed in the TTFields-treated cells, resulting in a reduction in cell migration and invasion by decreasing EMT- and ECM- related marker expression and reducing angiogenesis (Figure 1D)[34].

TTFields intervene autophagy process

Abnormal mitotic events can invite autophagy to occur (Figure 1E)[37]. When exposed to TTFields, the expression of autophagosome marker LC-II/LC-I was increased and the cells exhibited typical signs of autophagy[38]. Akt2/mTOR/p70S6K axis (a negative regulator of autophagy) is a vital regulator of autophagy by TTFields. Moreover, many miRNAs can be induced by TTFields, especially miR-29b which directly target Akt2 to trigger autophagy[39]. In most cases, autophagy can maintain the organization and stability of the centrosome to protect cells[40], while in the presence of the autophagy inhibitor 3-methyladenine, the number of dead GBM cells treated with TTFields was diminished, indicating that autophagy mediated TTFields-induced cell death[38]. Such called "autophagic programmed death" may be an alternative to programmed cell death[41].

However, inconsistent findings have been reported. Some studies proposed that autophagic flux might be interrupted by TTFields[14]. Autophagy may be a protective mechanism of cells against TTFields in some cases. Phosphorylated AMP-dependent kinase (AMPK) can inhibit mTORC1, thereby suppressing its ability to negatively regulate autophagy. Depletion of AMPK inhibits the up-regulation of autophagy in response to TTFields and sensitized GBM cells to treatment[42]. It is unknown whether autophagy exerts a protective or killing effect on TTFields-treated cancer cells and may be relevant to the genetic traits of cancer cells,

remains to be further investigated.

TTFIELDS induce anti-tumor immune response

Systemic anti-tumor immune responses can be activated in TTFIELDS-treated tumor-bearing animals (Figure 1F)[31]. High doses of dexamethasone could interfere with the therapeutic effect of TTFIELDS on rGBM[43]. In TTFIELDS-treated cells, damage-related molecular patterns including high-mobility group box 1 (HMGB1) and ATP were released, and calreticulin was exposed on the cell surface leading to increased infiltration of antigen-presenting cells into the tumor. Endoplasmic reticulum stress induced by TTFIELDS may be the trigger that drives exposure of calreticulin to the cell surface[44]. The dying cells release ATP, which serves as a “find me” signal of apoptotic cells to increase the recruitment of lymphocytes to induce immunogenic cell death of cells[45]. Furthermore, cell death caused by TTFIELDS can promote the maturation and phagocytosis of dendritic cells[44].

Emerging evidence suggested that TTFIELDS fostered the activation of RAW 264.7 macrophages and its output of NO and ROS. When co-cultured with 4TI cells under TTFIELDS, macrophages secreted elevated levels of pro-inflammatory cytokines, like IL-1 β , TNF- α , and IL-6, and the viability of 4TI cells were diminished. Besides, the phosphorylation levels of I κ B- α , NF- κ B p65 subunit, and p38 MAPK were observed higher in TTFIELDS-treated RAW 264.7 cells than control, indicating that TTFIELDS induced the p38 MAPK/NF- κ B pathway of macrophages to exert inflammatory effects[46].

Recently, TTFIELDS were reported to cause local disruption of the nuclear envelope of cancer cells during interphase, resulting in the release of large cytoplasmic clusters of naked micronuclei, which recruited and activated two major DNA sensors (cGAS and AIM2). Subsequently, the activated cGAS/STING inflammatory some tended to up-regulate pro-inflammatory cytokines, type 1 interferons (T1IFNs) and T1IFN-responsive genes, thereby activating the peripheral immune system and creating a potential intrinsic immune platform for cancers[47] (Figure 1C).

TTFIELDS increase cell membrane permeability

When applying high pulsed EF to the cells, depending on the field intensity, irreversible electroporation, induction of necrotic cell death, or reversible electroporation may occur[48]. In TTFIELDS-treated glioblastoma cells, the number and size of membrane pores were reversibly increased, allowing greater permeability to substances as large as 20 kDa (e.g., 5-aminolevulinic acid) but not exceeding 50 kDa (Figure 1G)[49]. Interestingly, the effect was tumor-specific and did not appear on normal cells. EF-induced transient increase in plasma membrane permeability, with contributions from structural rearrangement of lipids and protein changes, causing fatigue of the membrane structure[48]. Since the membrane composition of cancer cells is altered and more deformable than normal cells that may help in explaining the inconsistent response to alternating EF[48]. The cell membrane permeability of tumor cells increases in response to TTFIELDS, allowing transmembrane transport of chemical agents that explaining the increased efficacy of other drugs to some extent. The cell-membrane permeabilization also contributes to the release of innate tumor antigens and activates the immune system[50].

Ion channels in cell membrane can be affected by alternating EF, and the L-type Ca²⁺ channels CACNA1C (Cav1.2) were identified as TTFIELDS target recently[51], thereby influencing cell cycle progression, cell migration, and clonogenic survival of GBM cells[52]. Cell membrane potential is a key factor controlling the switching on and off of ion channels in cell membranes, and has been identified as a target for TTFIELDS. Using the Schwan equation, it was found that in tumor cells, TTFIELDS-induced changes in cell membrane potential can be much higher than 10% of the resting cell membrane potential, thus affecting intracellular ion homeostasis[53].

TTFIELDS were also reported to disrupt tight junction proteins (e.g., claudin 5 and ZO-1) of the BBB to increase the permeability of brain (Figure 1H)[54]. Till now, the presence of BBB has posed limitations for the treatment of brain malignancies and the cerebral application of some agents. TTFIELD-induced opening of BBB is similarly reversible and expands the range of intracranial drug application.

FACTORS AFFECTING THE EFFICACY OF TTFIELDS

The efficacy of TTFields depends on the specific parameters. For different types and sites of tumors, different modalities are set to obtain optimal efficacy. The optimal intensity of EF is different for different cancer cells. Mouse melanoma cells and rat glioma cells completely stop proliferating at 1.35 V/cm and 2.25 V/cm respectively[7], while human non-small cell lung cancer and breast cancer cells require higher[21]. The frequency range for anti-tumor effects in most cancers is 100 to 200 kHz[55, 56] (e.g., 200kHz for human GBM clinically, 120kHz for melanoma cells[7]). In vitro studies have shown that different GBM cell lines have different optimal electrical frequencies, 200 kHz for KNS42 and GIN-31, 400 kHz for SF18, and 100 kHz for U87[57, 58]. The optimal frequency of alternating EF is inversely proportional to the size of cancer cell[7]. Additionally, the inhibitory effect of tumor proliferation by TTFields is time-dependent[22, 59], and the effect of EF is strongest when the direction of EF is parallel to the axis of cell division. Given the polarity of tumor cells during the division cycle is irregular, applying EF in different directions is an effective way to increase the efficacy of treatment for patients[7]. Sequential application of multiple EF directions every 0.25~1.00s can make the splitting axis of more cells parallel to the direction of EF[21].

CLINICAL STUDIES OF TTFIELDS IN MALIGNANT BRAIN TUMORS

Along with a deeper understanding of the mechanism of action of TTFields, translational studies accompanying clinical trials are crucial for TTFields and are being vigorously pursued. The results of published clinical scientific researches TTFields therapy in brain malignancies, have been summarized in Table I. The ongoing clinical trials to further evaluate the safety and efficacy of TTFields-based combination therapy have been listed in Table II.

Recurrence glioblastoma (rGBM)

Defined as a grade IV glioma, GBM has a high recurrence rate. There is no consensus for the optimal treatment of rGBM, and the only FDA-approved agent is bevacizumab (a targeted VEGF antibody)[60, 61]. GBM diffusely infiltrates the brain and rarely metastasizes extracranially, thus is amenable to TTFields therapy[62]. The pilot trial of TTFields therapy was on 10 patients with rGBM, and median time to disease progression was 26.1 weeks and mean overall survival (OS) was 62.2weeks, higher than the reported medians of historical control patients[21]. In the randomized phase III clinical trial (EF-11, NCT00379470), 237 patients with rGBM were enrolled into two arms: TTFields versus best physician's choice chemotherapy (BPC), include bevacizumab, irinotecan, nitrosurea, carboplatin and TMZ. The results showed that OS and progression-free survival (PFS) of patients in two arms were similar (6.6 vs 6.0months, 2.2 vs 2.1months, respectively; $p > 0.05$)[8]. Although no improvement was observed in the EF-11 trial, the better quality of life (QoL) and lighter toxicity favoured the TTFields when compared with chemotherapy as an option in maintenance phase. Of note, most of the recruited patients were in advanced stages of the disease (failure of more than 2 chemotherapy agents), and there was heterogeneity in the patients population. In the OptimalTTF-1 trial (NCT02893137), the combination of cranial remodeling surgery with TTFields and BPC in patients with rGBM yielded an OS of 15.5 months and PFS of 4.6 months[63], much higher than that of TTFields arm in EF-11, and was well tolerated by patients[8]. The removal of standard craniotomy bone flap increased the EF intensity at the tumor site and was more effective with multiple smaller burr holes than with a single craniectomy[63]. Since the new multimodal approach has showed a preliminary survival benefit, a large-scale randomized, controlled trials, phase 2 trial (OptimalTTF-2, NCT0422399) was initiated 2 years ago to valid the novel combination therapy[64].

New diagnosed glioblastoma (ndGBM)

The standard of care (SOC) for ndGBM is maximal surgical resection, 6 weeks of postoperative RT and temozolomide (TMZ), and 6 months of TMZ maintenance therapy[65]. In a phase III trial of ndGBM (EF-14, NCT00916409), 695 patients after completion of chemoradiotherapy were enrolled into two arms randomly. Compared with standard TMZ maintenance therapy alone, adding TTFields to standard TMZ maintenance therapy dramatically improved OS (19.6 vs 16.6 months, respectively; $p < 0.001$) and PFS (7.1 vs 4.0 months, respectively; $p < 0.001$) of patients[9]. Excitingly enough, the DNA repair protein O⁶-methyl-

guanine DNA methyltransferase (MGMT), which has previously been reported to affect the efficacy of TMZ, did not affect TTFields[38]. EF-14 is the landmark trial of TTFields therapy, and the NOA-09/CeTeG trial published recently have verified the feasibility of combination of lomustine and TMZ[66]. Therefore, the combination of TTFields, lomustine and TMZ during maintenance phase was tested, and the observed PFS was 20 months in 16 patients with MGMT promoter methylated ndGBM that might suggested the potential benefit of the triple maintenance therapy[66].

TTFields are a promising candidate radiosensitizer, as it induced an abnormal increase in mitotic catastrophe and DNA damage of cells[25]. A prospective, single-arm study that recruited 10 patients with ndGBM was conducted to assess the feasibility and safety of combined RT and TTFields therapy with maintenance TMZ and TTFields. The mean PFS of this trial was 8.9 months and limited toxicity reported[67]. When TTFields were given concurrently with RT which was delivered through the TTFields arrays and with maintenance TMZ, the improvement in PFS of 9.3 months was illustrated[68]. It follows that the feasibility of TTFields both as maintenance therapy and alongside chemoradiotherapy is endorsed by prior clinical practice, and more large-scale clinical trial, EF-32(NCT04471844), is underway.

Other gliomas

Mesenchymal astrocytoma (MA) is a WHO grade III glioma, and the experience with the application of TTFields to MA is limited. A published clinical case for the first time reported that TTFields-based combination therapy delayed pathological up-gradation from anaplastic astrocytoma to GBM and prolonged PFS to nearly 10 months[69]. This case indicated the potential beneficial of TTFields-based therapy in MA, and ongoing trials of TTFields in a larger cohort of patients with MA are needed to be evaluated.

Ganglioglioma is classified as grade I, although grow slowly, some patients will experience recurrence or malignant progression. Transformation of ganglioglioma to high-grade glioma is rare but usually with poor prognosis[70]. A patient with a BRAF V600E mutation in a high-grade glioma originating from ganglioneuroma was treated with dabrafenib (a selective inhibitor of BRAF V600E) and TTFields after the failure of TMZ-based therapy. More than 2 years of follow-up have shown complete response to the combination therapy[71], arguing that gene-targeted treatment in combination with TTFields therapy may provide great clinical benefit for glioma with rare variants.

Metastatic tumors

The majority of brain metastases result from lung cancer[72]. The development of brain metastases complicates many solid tumors, and attribute to the death of patients with advanced cancer[73]. A METIS trial enrolling non-small cells lung cancer (NSCLC) patients with 1-10 brain metastases (NCT02831959) who receive stereotactic radiosurgery (SRS) followed by TTFields (150 kHz, [?]18 hours/day) or supportive care within 7 days of SRS reported no safety issues in 2018 and is ongoing currently[74].

PRECLINICAL STUDIES OF TTFIELDS IN MALIGNANT BRAIN TUMORS

With optimal output pattern, TTFields could significantly inhibited the viability, proliferation, and invasiveness of different cell lines, irrespective of their genetic traits[75]. Several studies have shown synergistic effects of TTFields and targeted agents, of which bevacizumab is widely applied[76, 77]. Sorafenib is a multi-kinase inhibitor and a first-line agent for the treatment of high-grade gliomas as well, but it has failed to improve outcomes when combined with TMZ[78]. While combining with TTFields, sorafenib significantly inhibited motility, invasiveness, and angiogenesis of GBM cells[79]. Evolutionary conserved protein kinase monopolar spindle 1 (MPS1) inhibition, affecting mitotic processes similarly, when combined with TTFields to GBM cells caused more than just additive effects. The anti-proliferative benefit of the combination therapy begins to work earlier than that of the mono-therapy[80]. Some inhibitors of MPS1 have been developed and can potentially serve as a bridge for TTFields therapy interruption. Likewise, hyperthermia has been reported to increase the efficacy of other approaches against cancers. Combining heat therapy with TTFields has been reported to enhance each other's therapeutic effects and inhibit the metastasis of GBM cells[81]. The combination of these two physical therapy may be easily tolerated by patients. Since Ca^{2+} channels contributes

to cellular stress response to TTFields, combining TTFields with Ca^{2+} antagonists (e.g., benidipine) may augment the efficacy and outcome of TTFields[51]. It provides the possibility of combining TTFields with Ca^{2+} antagonists which are already applied in clinical. In brief, TTFields hold great promise to address the challenge across the spectrum of the management of patients with high-grade gliomas by optimizing other treatment strategies.

Given the special immune environment of intracranial tumors, brain malignancies suppress immune cells activity and anti-cancer function, and revitalizing central immune system has become the emerging for malignant brain tumors and experienced tremendous growth[2]. Considering the transformation of tumors under TTFields exposure to a state more favorable for anti-tumor immune response[47], and its role of switching on the BBB, TTFields may potentially enhance the central anti-tumor immune response[54, 82]. At present, immunotherapeutic approaches for GBM contain: vaccines, checkpoint inhibitors, CAR-T cells, and oncolytic viruses[2]. Combining TTFields and anti-PD-1 (programmed cell death protein 1) therapy has already been proven validity in the resistance to extra-cranial tumors than single therapy by triggering immune response[44]. Several clinical trials (e.g., NCT03223103, NCT03405792) to test the immunogenicity and safety of immunotherapeutic approaches in combination with TTFields in patients with malignant brain tumors are conducted currently, which will be valuable to establish a combination of therapeutic strategies and to elucidate the mechanism of TTFields on the immune micro-environment of malignant brain tumors.

THERAPEUTIC EVALUATION OF TTFIELDS THERAPY

Magnetic resonance imaging (MRI) is the common method for diagnostics and follow-up of malignant brain diseases, especially the change of MRI contrast enhancement, which is often considered an indicator of treatment response or tumor progression[83]. But conventional MRI cannot assess treatment response reliably due to lack of specificity[84], and the enhancement can be caused by other non-tumor-associated processes[85]. Physiological imaging techniques, including diffusion tensor imaging (DTI), dynamic susceptibility contrast-perfusion weighted imaging (DSC-PWI) and proton MR spectroscopy, have great potential in assessing treatment response to different therapies in patients with GBM. A case reported the experience in evaluating treatment response to TTFields in combination with TMZ in a female ndGBM patient using DTI, DSC-PWI and 3D-echo-planar spectroscopic imaging. Compared with baseline, increased mean diffusivity and decreased fractional anisotropy, maximum relative cerebral blood volume, and reduced choline/creatine were noted at 2 months follow-up periods[86]. The results verified the synergistic effect of TTFields and TMZ chemotherapy can inhibit the growth of tumor.

Positron emission tomography (PET) scanning provides more biological information than just anatomical information in a non-invasive way[87]. As the most widely clinical applied tracer, ^{18}F -FDG (^{18}F -2-fluoro-2-deoxy-D-glucose) can be highly taken up by normal brain tissue, thus limiting the application in patients with malignant brain tumor[88]. The Response Assessment in Neuro-Oncology group have recommended more wide-scale diagnostic access to amino acids-based PET for the management of patients with malignant brain tumors[89], due to the low uptake by normal brain tissue[90]. When applied FET (O-(2- ^{18}F -fluoroethyl)-L-tyrosine) PET scanning in patients with high-grade glioma whose treatment included TTFields, the data showed increased tumor volume with increased uptake or metabolic activity and demonstrated with histologically or clinically follow-up confirmed disease progression. Compared to MRI images, FET PET images present clearer lesion boundaries (Figure 2)[91]. AMT (alpha[C-11]-methyl-L-tryptophan) PET scanning has been proven to detect an early metabolic response in rGBM patients before and after TTFields. The images indicated that AMT PET can detect the metabolic alterations of amino acids in GBM cells induced by TTFields earlier than MRI, therefore helps in clinical decision making, especially in cases where MRI images are inconclusive[92]. ^{18}F -DASA-23 (1-((2-fluoro-6- ^{18}F -fluorophenyl)sulfonyl)-4-((4-methoxyphenyl)sulfonyl)piperazine) was introduced to provide the information of the level of pyruvate kinase M2 (PKM2)[93], which is preferentially expressed in cancer cells and contributes to anabolic glucose metabolism[94]. A research project working on manipulation of ^{18}F -DASA-23 radiotracer to detect the impairment of GBM glycolytic metabolism through down-regulation on the expression of PKM2 by TTFields was published[95]. This research first proved that TTFields can cause a shift in GBM metabolism from gly-

colysis to oxidative phosphorylation. Even in the presence of sufficient oxygen, cancer cells prefer to use the inefficient process of glycolysis for energy production[96], the so-called warburg effect, which produces lactic acid that is beneficial for tumor growth and metastasis[97]. Warburg effect attribute to the tumor progression and provide suitable and appropriate atmosphere for tumor to metastasize. Therefore, the metabolic reprogramming of tumor cells by TTFields may also be one of its significant anti-cancer mechanisms.

TTFIELDS IMPROVE THE QUALITY OF PATIENT’S LIFE

Till now, accumulating clinical experience have confirmed the safety of TTFields therapy, and no significantly life-threatening TTFields-related event has been reported[8, 9]. The most frequent TTFields-related side effect is skin reaction[98], while other therapies often cause serious systematic side effects. The array-associated skin toxicity including rash, irritation, erythema, pruritus, contact dermatitis, ulceration, infection and skin breakdown, that could be cured with topical corticosteroid creams, topical and oral antibiotics, and isolation the affected skin surface from adhesives or pressure[99]. In brief, TTFields are linked to prolonged survival outcomes, minimal adverse effects and easily manageable.

According to the patient registration dataset, the clinical efficacy of TTFields on patients was significantly improved with [?]75% daily adherence ([?]18 hours/day) compared with <75%[100]. In other words, the efficacy of TTFields on patients with brain malignancies critically depends on their high compliance rate, and patients must abide by a long daily regimen of continuous TTFields for at least 4 weeks that might bring inconvenience for patients. To improve the ease of use, home medical devices were developed, allowing patients to receive treatment by simply wearing the devices on their heads and not interfering with their daily activities. The most commonly employed TTFields delivery system consists of four transducer arrays, a field generator, and a power resource. The distribution of the arrays can be determined by the NovoTAL software to ensure that the best field strength is obtained at the tumor site[13]. EF is delivered through the transducer arrays attached to the skin, and patients with lesions in the brain need to make an adequate commitment to daily skin care, regular hair shaving, and carrying sufficient power sources during TTFields therapy. Fortunately, according to the analysis of EF-14 trial, adding TTFields to cancer treatment does not worsen patient function and well-being production, such as role, social, and physical functioning[98]. Patients can enjoy symptomatically stability during TTFields therapy, meanwhile, their quality of life can be maintained.

Since late 2019, the COVID-19 epidemic has forced a change in the treatment paradigm brought about by quarantine limitations, that might become the barrier to the routine treatment of patients with cancer. TTFields can be administered via telemedicine and confer a competitive advantage to be conveniently employed for the management of GBM patients during the COVID-19 pandemic[101]. Furthermore, reducing patient visits to health care facilities and cutting down on potential exposure to virus will ensure the safety of ongoing treatment.

CONCLUSION

As a noninvasive physical therapy, TTFields have exhibited unique advantages in the treatment of patients with malignant brain tumors and are well suited for clinical trials exploring combined approaches to the management of patients due to the minor adverse effects and absence of toxicity. Nevertheless, the application of TTFields in pediatric high-grade glioma is relatively rare, with few case reports regarding safety analysis, and needs to be corroborated in a larger patient cohort[102]. TTFields do not have a half-life and enable sustainable treatment[103], which can be applied between chemoradiotherapy or concurrently with RT[104]. Furthermore, TTFields are inherently non-specific to tumor types, may cause therapeutic effects for a wide range of solid tumors, and are being investigated for application to extra cranial tumors[44, 56, 105]. Unfortunately, the mechanism of TTFields is far less clear and suffers from skepticism than other therapies[106]. Pharmacological profiling may be helpful in revealing the synergistic effects of TTFields in combination with other therapeutic agents. Continued enhancement of research and understanding of the molecular mechanisms will facilitate the adoption of this novel therapy for integration into existing or new treatment strategies.

Although already an established treatment for newly diagnosed or recurrent GBM in adults by FDA and have been proven effective in combination with SOC of GBM, TTFields were not added to SOC by the leading experts[104]. High cost is the biggest obstacle to broadening the application of TTFields, which needs to be addressed immediately, and cost-effectiveness studies are recommended[107, 108]. To improve the convenience of use, further refinement of the TTFields system is required to improve the ease of use and device performance through physical and other means (e.g., changing the size and weight of the instrument, the implanting of electrodes around the tumor). Conducting an outpatient clinic for TTFields therapy consultation is suggested, which may lead to a great promotion of motivation and compliance rate, and ensures the clinical efficacy of TTFields[109]. Besides, it's still a mission for researchers to figure out the biomarkers to select the suitable patients who might be responsive to TTFields, and the markers or technique predicting optimal frequency or response in different cancer types or individuals. The framework of TTFields therapy, from patient selection and treatment to follow-up efficacy assessment system, needs to be refined in detail. As a innovative treatment with great potential for tumor therapy, we firmly believe that TTFields treatment system will be a boon to patients with cancer.

Ethical statement

Not applicable.

Data availability statement

Not applicable.

Acknowledgments

Not applicable.

Funding information

This work was supported by National Natural Science Foundation of China (81725009, 21788102 and 82030049), and National Key R&D Program of China (2021YFE0108300).

Conflicts of interest

The authors declare that there is no conflict of interest.

References

1. Ostrom Q, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. *Neuro-oncology*. 2014;iv1-63.
2. Ljubimov V, Ramesh A, Davani S, Danielpour M, Breunig J, Black K. Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic. *Advanced drug delivery reviews*. 2022;181:114033.
3. Rivoirard R, Vallard A, Langrand-Escure J, Ben Mrad M, Wang G, Guy J, et al. Thirty years of phase I radiochemotherapy trials: Latest development. *European journal of cancer (Oxford, England : 1990)*. 2016;58:1-7.
4. Sun G, Rong D, Li Z, Sun G, Wu F, Li X, et al. Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges. *Frontiers in cell and developmental biology*. 2021;9:694363.
5. Lin X, DeAngelis LM. Treatment of Brain Metastases. *J Clin Oncol*. 2015;33(30):3475-84.
6. Arvanitis CD, Ferraro GB, Jain RK. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. *Nat Rev Cancer*. 2020;20(1):26-41.
7. Kirson E, Gurvich Z, Schneiderman R, Dekel E, Itzhaki A, Wasserman Y, et al. Disruption of cancer cell replication by alternating electric fields. *Cancer research*. 2004;64(9):3288-95.

8. Stupp R, Wong E, Kanner A, Steinberg D, Engelhard H, Heidecke V, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. *European journal of cancer* (Oxford, England : 1990). 2012;48(14):2192-202.
9. Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. *JAMA*. 2017;318(23):2306-16.
10. Kutuk T, Appel H, Avendano M, Albrecht F, Kaywin P, Ramos S, et al. Feasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Single-Center, Real-World Data. *Cancers*. 2022;14(8).
11. Robinson AJ, Jain A, Sherman HG, Hague RJM, Rahman R, Sanjuan-Alberte P, et al. Toward Hijacking Bioelectricity in Cancer to Develop New Bioelectronic Medicine. *Advanced Therapeutics*. 2021;4(3):2000248.
12. Levin M, Stevenson CG. Regulation of Cell Behavior and Tissue Patterning by Bioelectrical Signals: Challenges and Opportunities for Biomedical Engineering. *Annual Review of Biomedical Engineering*. 2012;14(1):295-323.
13. Davies A, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. *Annals of the New York Academy of Sciences*. 2013;1291:86-95.
14. Xu S, Luo C, Chen D, Tang L, Chen L, Liu Z. Whole transcriptome and proteome analyses identify potential targets and mechanisms underlying tumor treating fields against glioblastoma. *Cell Death Dis*. 2022;13(8):721.
15. Gutin P, Wong E. Noninvasive application of alternating electric fields in glioblastoma: a fourth cancer treatment modality. *American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting*. 2012:126-31.
16. Kline-Smith S, Walczak C. Mitotic spindle assembly and chromosome segregation: refocusing on microtubule dynamics. *Molecular cell*. 2004;15(3):317-27.
17. Barreca M, Stathis A, Barraja P, Bertoni F. An overview on anti-tubulin agents for the treatment of lymphoma patients. *Pharmacology & therapeutics*. 2020;211:107552.
18. Voloshin T, Schneiderman R, Volodin A, Shamir R, Kaynan N, Zeevi E, et al. Tumor Treating Fields (TTFields) Hinder Cancer Cell Motility through Regulation of Microtubule and Actin Dynamics. *Cancers*. 2020;12(10).
19. Tooley A, Gilden J, Jacobelli J, Beemiller P, Trimble W, Kinoshita M, et al. Amoeboid T lymphocytes require the septin cytoskeleton for cortical integrity and persistent motility. *Nature cell biology*. 2009;11(1):17-26.
20. Gilden J, Peck S, Chen Y, Krummel M. The septin cytoskeleton facilitates membrane retraction during motility and blebbing. *The Journal of cell biology*. 2012;196(1):103-14.
21. Kirson E, Dbalý V, Tovarys F, Vymazal J, Soustiel J, Itzhaki A, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. *Proceedings of the National Academy of Sciences of the United States of America*. 2007;104(24):10152-7.
22. Giladi M, Schneiderman R, Voloshin T, Porat Y, Munster M, Blat R, et al. Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells. *Scientific reports*. 2015;5:18046.
23. Gera N, Yang A, Holtzman T, Lee S, Wong E, Swanson K. Tumor treating fields perturb the localization of septins and cause aberrant mitotic exit. *PloS one*. 2015;10(5):e0125269.

24. Lee SX, Wong ET, Swanson KD. MITOSIS INTERFERENCE OF CANCER CELLS DURING ANAPHASE BY ELECTRIC FIELD FROM NOVOTTF-100A. *NEURO-ONCOLOGY*. 2011;13:13-4.
25. Kim E, Kim Y, Song H, Jeong Y, Lee J, Sung J, et al. Biological effect of an alternating electric field on cell proliferation and synergistic antimitotic effect in combination with ionizing radiation. *Oncotarget*. 2016;7(38):62267-79.
26. Giladi M, Munster M, Schneiderman R, Voloshin T, Porat Y, Blat R, et al. Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells. *Radiation oncology* (London, England). 2017;12(1):206.
27. Karanam N, Srinivasan K, Ding L, Sishc B, Saha D, Story M. Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines. *Cell death & disease*. 2017;8(3):e2711.
28. Zhao W, Steinfeld J, Liang F, Chen X, Maranon D, Jian Ma C, et al. BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing. *Nature*. 2017;550(7676):360-5.
29. Kais Z, Rondinelli B, Holmes A, O'Leary C, Kozono D, D'Andrea A, et al. FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair. *Cell reports*. 2016;15(11):2488-99.
30. Karanam N, Ding L, Aroumougame A, Story M. Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: Implications for cancer therapy. *Translational research : the journal of laboratory and clinical medicine*. 2020;217:33-46.
31. Kirson E, Giladi M, Gurvich Z, Itzhaki A, Mordechovich D, Schneiderman R, et al. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. *Clinical & experimental metastasis*. 2009;26(7):633-40.
32. Shi P, Tian J, Ulm B, Mallinger J, Khoshbouei H, Deleyrolle L, et al. Tumor Treating Fields Suppression of Ciliogenesis Enhances Temozolomide Toxicity. *Frontiers in oncology*. 2022;12:837589.
33. Kalluri R, Weinberg R. The basics of epithelial-mesenchymal transition. *The Journal of clinical investigation*. 2009;119(6):1420-8.
34. Kim E, Song H, Yoo S, Yoon M. Tumor treating fields inhibit glioblastoma cell migration, invasion and angiogenesis. *Oncotarget*. 2016;7(40):65125-36.
35. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. *Nature reviews Cancer*. 2002;2(3):161-74.
36. Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. *Vascular health and risk management*. 2006;2(3):213-9.
37. Inoue T, Nakayama Y, Li Y, Matsumori H, Takahashi H, Kojima H, et al. SIRT2 knockdown increases basal autophagy and prevents postslippage death by abnormally prolonging the mitotic arrest that is induced by microtubule inhibitors. *The FEBS journal*. 2014;281(11):2623-37.
38. Silginer M, Weller M, Stupp R, Roth P. Biological activity of tumor-treating fields in preclinical glioma models. *Cell death & disease*. 2017;8(4):e2753.
39. Kim E, Jo Y, Sai S, Park M, Kim J, Kim J, et al. Tumor-treating fields induce autophagy by blocking the Akt2/miR29b axis in glioblastoma cells. *Oncogene*. 2019;38(39):6630-46.
40. Holdgaard S, Cianfanelli V, Pupo E, Lambrugh M, Lubas M, Nielsen J, et al. Selective autophagy maintains centrosome integrity and accurate mitosis by turnover of centriolar satellites. *Nature communications*. 2019;10(1):4176.

41. Tsujimoto Y, Shimizu S. Another way to die: autophagic programmed cell death. *Cell Death & Differentiation*. 2005;12(2):1528-34.
42. Shteingauz A, Porat Y, Voloshin T, Schneiderman R, Munster M, Zeevi E, et al. AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields). *Cell death & disease*. 2018;9(11):1074.
43. Wong E, Lok E, Gautam S, Swanson K. Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma. *British journal of cancer*. 2015;113(2):232-41.
44. Voloshin T, Kaynan N, Davidi S, Porat Y, Shteingauz A, Schneiderman R, et al. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. *Cancer immunology, immunotherapy : CII*. 2020;69(7):1191-204.
45. Martins I, Wang Y, Michaud M, Ma Y, Sukkurwala A, Shen S, et al. Molecular mechanisms of ATP secretion during immunogenic cell death. *Cell death and differentiation*. 2014;21(1):79-91.
46. Park J, Song K, Jung S, Ahn J, Hwang S, Kim J, et al. Tumor-Treating Fields Induce RAW264.7 Macrophage Activation Via NK- α B/MAPK Signaling Pathways. *Technology in cancer research & treatment*. 2019;18:1533033819868225.
47. Chen D, Le S, Hutchinson T, Calinescu A, Sebastian M, Jin D, et al. Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma. *The Journal of clinical investigation*. 2022.
48. Aguilar AA, Ho MC, Chang E, Carlson KW, Natarajan A, Marciano T, et al. Permeabilizing Cell Membranes with Electric Fields. *Cancers (Basel)*. 2021;13(9).
49. Chang E, Patel C, Pohling C, Young C, Song J, Flores T, et al. Tumor treating fields increases membrane permeability in glioblastoma cells. *Cell death discovery*. 2018;4:113.
50. Probst U, Fuhrmann I, Beyer L, Wiggermann P. Electrochemotherapy as a New Modality in Interventional Oncology: A Review. *Technology in cancer research & treatment*. 2018;17:1533033818785329.
51. Neuhaus E, Zirjacks L, Ganser K, Klumpp L, Schüler U, Zips D, et al. Alternating Electric Fields (TTFields) Activate Ca_v1.2 Channels in Human Glioblastoma Cells. *Cancers*. 2019;11(1).
52. Chinigò G, Castel H, Chever O, Gkika D. TRP Channels in Brain Tumors. *Front Cell Dev Biol*. 2021;9:617801.
53. Li X, Yang F, Rubinsky B. A Theoretical Study on the Biophysical Mechanisms by Which Tumor Treating Fields Affect Tumor Cells During Mitosis. *IEEE transactions on bio-medical engineering*. 2020;67(9):2594-602.
54. Kessler AF, Salvador E, Domrose D, Burek M, Schaeffer C, Bami CT, et al. Blood Brain Barrier (BBB) Integrity Is Affected By Tumor Treating Fields (TTFields) in Vitro and In Vivo. *International Journal of Radiation Oncology Biology Physics*. 2019;105(1):S162-S3.
55. Ceresoli G, Aerts J, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck J, et al. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. *The Lancet Oncology*. 2019;20(12):1702-9.
56. Giladi M, Schneiderman R, Porat Y, Munster M, Itzhaki A, Mordechovich D, et al. Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields. *Pancreatology : official journal of the International Association of Pancreatology (IAP) [et al]*. 2014;14(1):54-63.
57. Akbarnejad Z, Eskandary H, Dini L, Vergallo C, Nematollahi-Mahani S, Farsinejad A, et al. Cytotoxicity of temozolomide on human glioblastoma cells is enhanced by the concomitant exposure to an extreme-

- ly low-frequency electromagnetic field (100Hz, 100G). *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*. 2017;92:254-64.
58. Branter J, Estevez-Cebrero M, Diksin M, Griffin M, Castellanos-Urbe M, May S, et al. Genome-Wide Expression and Anti-Proliferative Effects of Electric Field Therapy on Pediatric and Adult Brain Tumors. *International journal of molecular sciences*. 2022;23(4).
59. Kirson ED, Wasserman Y, Izhaki A, Mordechovich D, Gurvich Z, Dbaly V, et al. Modeling tumor growth kinetics and its implications for TTFields treatment planning. *Neuro-Oncology*. 2010:48-.
60. Norden A, Young G, Setayesh K, Muzikansky A, Klufas R, Ross G, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. *Neurology*. 2008;70(10):779-87.
61. Iwamoto F, Abrey L, Beal K, Gutin P, Rosenblum M, Reuter V, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. *Neurology*. 2009;73(15):1200-6.
62. Rosen J, Blau T, Grau S, Barbe M, Fink G, Galldiks N. Extracranial Metastases of a Cerebral Glioblastoma: A Case Report and Review of the Literature. *Case reports in oncology*. 2018;11(2):591-600.
63. Korshoej A, Lukacova S, Lassen-Ramshad Y, Rahbek C, Severinsen K, Guldberg T, et al. OptimalTTF-1: Enhancing tumor treating fields therapy with skull remodeling surgery. A clinical phase I trial in adult recurrent glioblastoma. *Neuro-oncology advances*. 2020;2(1):vdad121.
64. Mikic N, Poulsen F, Kristoffersen K, Laursen R, Guldberg T, Skjøth-Rasmussen J, et al. Study protocol for OptimalTTF-2: enhancing Tumor Treating Fields with skull remodeling surgery for first recurrence glioblastoma: a phase 2, multi-center, randomized, prospective, interventional trial. *BMC cancer*. 2021;21(1):1010.
65. Fisher J, Adamson D. Current FDA-Approved Therapies for High-Grade Malignant Gliomas. *Biomedicines*. 2021;9(3).
66. Lazaridis L, Schäfer N, Teuber-Hanselmann S, Blau T, Schmidt T, Oster C, et al. Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma. *Journal of cancer research and clinical oncology*. 2020;146(3):787-92.
67. Bokstein F, Blumenthal D, Limon D, Harosh C, Ram Z, Grossman R. Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility Study. *Frontiers in oncology*. 2020;10:411.
68. Miller R, Song A, Ali A, Niazi M, Bar-Ad V, Martinez N, et al. Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma. *Frontiers in oncology*. 2022;12:896246.
69. Lin Y, Chen B. Case report: tumor-treating fields prolongs IDH-mutant anaplastic astrocytoma progression-free survival and pathological evolution to glioblastoma. *Annals of translational medicine*. 2021;9(24):1804.
70. Majores M, von Lehe M, Fassunke J, Schramm J, Becker AJ, Simon M. Tumor recurrence and malignant progression of gangliogliomas. *Cancer*. 2008;113(12):3355-63.
71. Meletath S, Pavlick D, Brennan T, Hamilton R, Chmielecki J, Elvin J, et al. Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma. *Journal of the National Comprehensive Cancer Network : JNCCN*. 2016;14(11):1345-50.
72. Achrol A, Rennert R, Anders C, Soffietti R, Ahluwalia M, Nayak L, et al. Brain metastases. *Nature reviews Disease primers*. 2019;5(1):5.
73. Kirschenbaum D, Amit I. Brain metastases: Not all tumors are created equal. *Neuron*. 2022;110(7):1097-9.

74. Mehta M, Gondi V, Ahluwalia M, Brown P. Radiosurgery followed by tumour treating fields (TTFields) for brain metastases (1-10) from NSCLC in the phase III METIS trial. *Annals of Oncology*. 2019;30.
75. Wu H, Yang L, Liu H, Zhou D, Chen D, Zheng X, et al. Exploring the efficacy of tumor electric field therapy against glioblastoma: An in vivo and in vitro study. *CNS neuroscience & therapeutics*. 2021;27(12):1587-604.
76. Elzinga G, Wong E. Resolution of cystic enhancement to add-on tumor treating electric fields for recurrent glioblastoma after incomplete response to bevacizumab. *Case reports in neurology*. 2014;6(1):109-15.
77. Lu G, Rao M, Zhu P, Liang B, El-Nazer R, Fonkem E, et al. Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study. *Frontiers in neurology*. 2019;10:42.
78. Den R, Kamrava M, Sheng Z, Werner-Wasik M, Dougherty E, Marinucchi M, et al. A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas. *International journal of radiation oncology, biology, physics*. 2013;85(2):321-8.
79. Jo Y, Kim E, Sai S, Kim J, Cho J, Kim H, et al. Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy. *International journal of molecular sciences*. 2018;19(11).
80. Kessler A, Frömling G, Gross F, Hahn M, Dzokou W, Ernestus R, et al. Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition. *Cell death discovery*. 2018;4:12.
81. Jo Y, Han Y, Lee E, Seo J, Oh G, Sung H, et al. The combination of tumor treating fields and hyperthermia has synergistic therapeutic effects in glioblastoma cells by downregulating STAT3. *American journal of cancer research*. 2022;12(3):1423-32.
82. Lee J, Grabowski M, Lathia J. Tumor Treating Fields: killing two birds with one stone. *The Journal of clinical investigation*. 2022;132(8).
83. Wen P, Macdonald D, Reardon D, Cloughesy T, Sorensen A, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2010;28(11):1963-72.
84. Jackson E, Barboriak D, Bidaut L, Meyer C. Magnetic resonance assessment of response to therapy: tumor change measurement, truth data and error sources. *Translational oncology*. 2009;2(4):211-5.
85. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent M. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. *The Lancet Oncology*. 2008;9(5):453-61.
86. Mohan S, Chawla S, Wang S, Verma G, Skolnik A, Brem S, et al. Assessment of early response to tumor-treating fields in newly diagnosed glioblastoma using physiologic and metabolic MRI: initial experience. *CNS oncology*. 2016;5(3):137-44.
87. Tian M, He X, Jin C, He X, Wu S, Zhou R, et al. Transpathology: molecular imaging-based pathology. *Eur J Nucl Med Mol Imaging*. 2021;48(8):2338-50.
88. Werner J, Lohmann P, Fink G, Langen K, Galldiks N. Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors. *Molecules (Basel, Switzerland)*. 2020;25(6).
89. Langen K, Watts C. Neuro-oncology: Amino acid PET for brain tumours - ready for the clinic? *Nature reviews Neurology*. 2016;12(7):375-6.
90. Singhal T, Narayanan T, Jain V, Mukherjee J, Mantil J. 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. *Molecular imaging and biology*. 2008;10(1):1-18.

91. Ceccon G, Lazaridis L, Stoffels G, Rapp M, Weber M, Blau T, et al. Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience. *European journal of nuclear medicine and molecular imaging*. 2018;45(9):1626-35.
92. Bosnyák E, Barger G, Michelhaugh S, Robinette N, Amit-Yousif A, Mittal S, et al. Amino Acid PET Imaging of the Early Metabolic Response During Tumor-Treating Fields (TTFields) Therapy in Recurrent Glioblastoma. *Clinical nuclear medicine*. 2018;43(3):176-9.
93. Witney T, James M, Shen B, Chang E, Pohling C, Arksey N, et al. PET imaging of tumor glycolysis downstream of hexokinase through noninvasive measurement of pyruvate kinase M2. *Science translational medicine*. 2015;7(310):310ra169.
94. Christofk H, Vander Heiden M, Harris M, Ramanathan A, Gerszten R, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. *Nature*. 2008;452(7184):230-3.
95. Patel C, Beinat C, Xie Y, Chang E, Gambhir S. Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by [F]DASA-23, a non-invasive probe of pyruvate kinase M2 (PKM2) expression. *Neoplasia (New York, NY)*. 2021;23(1):58-67.
96. DeBerardinis R, Chandel N. We need to talk about the Warburg effect. *Nature metabolism*. 2020;2(2):127-9.
97. Xu K, Yin N, Peng M, Stamatiades E, Chhangawala S, Shyu A, et al. Glycolytic ATP fuels phosphoinositide 3-kinase signaling to support effector T helper 17 cell responses. *Immunity*. 2021;54(5):976-87.e7.
98. Taphoorn M, Dirven L, Kanner A, Lavy-Shahaf G, Weinberg U, Taillibert S, et al. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial. *JAMA oncology*. 2018;4(4):495-504.
99. Lacouture M, Davis M, Elzinga G, Butowski N, Tran D, Villano J, et al. Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma. *Seminars in oncology*. 2014:S1-14.
100. Toms S, Kim C, Nicholas G, Ram Z. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. *Journal of neuro-oncology*. 2019;141(2):467-73.
101. Gatson N, Barnholtz-Sloan J, Drappatz J, Henriksson R, Hottinger A, Hinoul P, et al. Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic. *Frontiers in oncology*. 2021;11:679702.
102. Green A, Mulcahy Levy J, Vibhakkar R, Hemenway M, Madden J, Foreman N, et al. Tumor treating fields in pediatric high-grade glioma. *Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery*. 2017;33(7):1043-5.
103. Wenger C, Miranda P, Salvador R, Thielscher A, Bomzon Z, Giladi M, et al. A Review on Tumor-Treating Fields (TTFields): Clinical Implications Inferred From Computational Modeling. *IEEE reviews in biomedical engineering*. 2018;11:195-207.
104. Mehta M, Wen P, Nishikawa R, Reardon D, Peters K. Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. *Critical reviews in oncology/hematology*. 2017;111:60-5.
105. Vergote I, von Moos R, Manso L, Van Nieuwenhuysen E, Concin N, Sessa C. Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study. *Gynecologic oncology*. 2018;150(3):471-7.
106. Wick W. TTFields: where does all the skepticism come from? *Neuro-oncology*. 2016;18(3):303-5.

107. Burri S, Gondi V, Brown P, Mehta M. The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists. *American journal of clinical oncology*. 2018;41(2):191-6.

108. Bernard-Arnoux F, Lamure M, Ducray F, Aulagner G, Honnorat J, Armoiry X. The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. *Neuro-oncology*. 2016;18(8):1129-36.

109. Haj A, Doenitz C, Hohenberger C, Brawanski A, Proescholdt MA. P01.144 TTFields for newly diagnosed Glioblastoma: Impact of consultation strategy. (1522-8517 (Print)).

110. Salzberg M, Kirson E, Palti Y, Rochlitz C. A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors. *Onkologie*. 2008;31(7):362-5.

Figure Legends

Figure 1: Diagram of the anti-cancer mechanism of TTFields. (A) During metaphase mitosis, tubulin will align in the direction of the EF, resulting in interference with its polymerization and thus impaired chromosome segregation. (B) During cell division, the cell morphology under TTFields (hourglass-like shape) produces an inhomogeneous intracellular EF, and all polar macromolecules and organelles will be pushed towards the CCF. In addition to interfering with mitosis, TTFields has multiple biological mechanisms, including: (C)inhibiting DSB repair, enhancing DNA replication pressure, (D)inhibiting tumor cell migration and metastasis, (E) promoting autophagy, and (F) inflammatory responses to kill tumor cells,(G) increasing cell membrane and (H) BBB permeability to facilitate the uptake of agents.

Figure 2: Images before TTFields and during follow-up of a 73-year-old patient with GBM.Due to an immune thrombocytopenia, only TTFields was applied 4 weeks after completion of radiotherapy with concomitant TMZ. Before TTFields, baseline FET PET images showed a slight increase in metabolic activity (TBRmax 2.0, TBRmean 1.6) without spatial counterpart contrast enhancement. Sequential FET PET images at 3 and 6 months follow-up showed a decrease in metabolic activity, as evidenced by a decreased tumor-to-brain ratio. Compared to MRI T1 images, FET PET images showed clearer lesions. Adapted permission from [ref. 91].

Table I: The summary of finished clinical studies of TTFields in brain tumors.

Study	Phase	Cancer type	Number of patients	The device, frequency, intensity, and exposure time of TTFields	Combining therapy	Outcomes	Refs
EF-02	Pilot study	rGBM	1	NovoTTF-100A device; Frequency: 100–200 kHz; Field intensity of 0.7 V/cm root mean square (RMS).	-	No response	[110]

EF-07	Pilot clinical trial		10	Not available.	-	Median time to disease progression: 26.1 weeks; Mean OS: 62.2weeks	[21]
EF-11	Randomised phase III clinical trial		TTFields arm: 120; TMZ arm: 117	NovoTTF-100A; Frequency:200 kHz; Field intensity:>0.7 V/cm at the centre of the brain.	-	Mean OS: 6.6 vs 6.0months; Mean PFS: 2.2 vs 2.1months.	[8]
-	Retrospective Study		TMZ/BEV/IRINOTECAN arm:18; BEV/TTFields arm: 30	NovoTTF-100A; Exposure time: >18 hours/ day.	Temozolomide, Bevacizumab, Irinotecan	Mean OS: 18.9months; Mean PFS: 10.7months.	[77]
	Pilot study		15	Optune; Frequency:200 kHz; a peak-to-peak current of 1.8–2 A.	Skull remodeling surgery	Mean OS: 15.5 months; Mean PFS: 4.6 months.	[63]
OptimalTTF-1							
EF-14	Randomised phase III clinical trial	ndGBM	TMZ/TTFields arm:466; TMZ arm: 229	NovoTTF-100A; Frequency: 200 kHz; Exposure time: [?]18 hours/day.	Temozolomide	Mean OS: 19.6 vs 16.6 months; Mean PFS: 7.1 vs 4.0 months.	[9]
-	Retrospective Study		16	Optune; [?]18 hours/day	Temozolomide, Lomustine	Mean PFS: 20months.	[66]
-	Pilot study		30	NovoTTF-200A; Frequency: 200 kHz; Exposure time: [?]18 hours/day.	Concurrent radiotherapy, Temozolomide.	Mean PFS: 9.3 months.	[68]

-	Pilot study	10	NovoTTF-200A; Frequency: 200 kHz; Exposure time: [?]18 hours/day.	Radiotherapy, Mean PFS: Temozolomide, 8.9 months.	[67]
---	-------------	----	--	--	------

Abbreviations. GBM: glioblastoma; rGBM: recurrence glioblastoma; ndGBM: newly-diagnosed glioblastoma; OS: overall survival; PFS: progression-free survival.

Table II: The summary of ongoing clinical trials of TTFields in brain tumors.

NCT number	Condition or disease	The device, frequency, intensity, and exposure time of TTFields	Combining therapy	status
NCT02831959	Non-small cell lung cancer brain metastasis	NovoTTF-200A; 150 kHz; >18 hours/day	Stereotactic radio surgery	Recruiting
NCT05341349	Melanoma brain metastases	NovoTTF-100M; [?]8hours/day	Ipilimumab, Nivolumab, Pembrolizumab, Stereotactic, Radiosurgery	Not yet recruiting
NCT04967027	Brain metastasis with drug/radiation resistant	ASCLU-300 TTF; [?]18hours/day	-	Recruiting
NCT04221503	GBM	Optune; [?]18hours/day	Niraparib, Planned surgical resection	Recruiting
NCT04689087	rGBM	Not mentioned	Second-line chemotherapy treatment	Recruiting
NCT04223999	First recurrence GBM	[?]18hours/day	Skullremodeling surgery	Recruiting
NCT04397679	ndGBM	[?]18hours/day	Partial Brain radiotherapy, Temozolomide, Chloroquine	Recruiting
NCT03405792	ndGBM	Optune; 24months	Temozolomide, Pembrolizumab	Active, not recruiting
NCT03223103	ndGBM	Optune	Poly-ICLC, Peptides	Active, not recruiting
NCT04671459	GBM and rGBM	Optune	Stereotactic radiosurgery	Recruiting
NCT05030298	Malignant Glioma	Not available	RT, TMZ, radiosurgery	Not yet recruiting
NCT04902586	Glioma and GBM	Low-intensity; 200 kHz; [?]18hours/day	Radiotherapy	Not yet recruiting

NCT04396860	Gliosarcoma and MGMT-unmethylated GBM	NovoTTF-100A	Ipilimumab, Nivolumab	Recruiting
NCT03033992	Paediatric malignant glioma ependymoma	NovoTTF-200A; [?]18hours/day	-	Recruiting
NCT05086497	GBM	Optune array layout mapping created from conventional/advanced MR imaging sequences	-	Not yet recruiting

All trials can be searched in ClinicalTrials.gov beta website (<https://clinicaltrials.gov/>).




Figure.1






Figure.2





Hosted file

Table I.docx available at <https://authorea.com/users/577931/articles/620126-therapeutic-potential-of-tumor-treating-fields-for-malignant-brain-tumors>

Hosted file

Table II.docx available at <https://authorea.com/users/577931/articles/620126-therapeutic-potential-of-tumor-treating-fields-for-malignant-brain-tumors>